Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07673263

Effects of X Box Kinect 360 in Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Alzheimer s Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Alzheimer's disease of age between 50-85 years.
  • Diagnosed AD stage Mild to Moderate.

Exclusion criteria

  • Undiagnosed AD patients.
  • Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.

Treatment and study plan

3D Kinect based game

Other

Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.

Conventional therapy group

Other

The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.

Primary outcomes

  1. Cognition

    Time frame: Baseline

    Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.

  2. Cognition

    Time frame: After 6 week of Intervention

    Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function

  3. Motor Function

    Time frame: Baseline

    Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility

  4. Motor Function

    Time frame: After 6 week of intervention

    Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility

  5. Quality of Life (QOL)

    Time frame: Baseline

    Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.

  6. Quality Of Life (QOL)

    Time frame: After 6 weeks of Intervention

    Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Silvia Peter William, Mphil

CONTACT

[email protected]

021-36629251 ext. 5

Sponsors and collaborators

Lead sponsor

Ziauddin University

Other

Registry information

Official study title

Effect of 3D Kinect Games With Google Cardboard on Motor Control, Cognition, and Quality of Life in Mild to Moderate Alzheimer's Patient

Acronym: AD Alzheimer'

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.